JP2022551757A5 - - Google Patents
Info
- Publication number
- JP2022551757A5 JP2022551757A5 JP2022522653A JP2022522653A JP2022551757A5 JP 2022551757 A5 JP2022551757 A5 JP 2022551757A5 JP 2022522653 A JP2022522653 A JP 2022522653A JP 2022522653 A JP2022522653 A JP 2022522653A JP 2022551757 A5 JP2022551757 A5 JP 2022551757A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- cdr2
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915120P | 2019-10-15 | 2019-10-15 | |
| US62/915,120 | 2019-10-15 | ||
| PCT/US2020/055480 WO2021076554A1 (en) | 2019-10-15 | 2020-10-14 | Antibodies targeting flt3 and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551757A JP2022551757A (ja) | 2022-12-13 |
| JP2022551757A5 true JP2022551757A5 (cg-RX-API-DMAC7.html) | 2023-10-19 |
Family
ID=75538063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522653A Ceased JP2022551757A (ja) | 2019-10-15 | 2020-10-14 | Flt3を標的とする抗体およびその使用 |
Country Status (16)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| JP2024532167A (ja) * | 2021-08-16 | 2024-09-05 | ヒーモジェニックス ファーマシューティカルズ エルエルシー | 抗flt3抗体、car、car t細胞、及び使用方法 |
| WO2023105087A1 (en) * | 2021-12-10 | 2023-06-15 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| CA2978631C (en) * | 2015-03-09 | 2023-06-27 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to flt3 proteins |
| WO2017011803A1 (en) * | 2015-07-16 | 2017-01-19 | Cellerant Therapeutics, Inc. | Cysteine-substituted immunoglobulins |
| JP7234142B2 (ja) * | 2017-06-02 | 2023-03-07 | ファイザー・インク | Flt3に特異的な抗体およびその使用 |
| PE20241587A1 (es) * | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| WO2019023097A1 (en) * | 2017-07-26 | 2019-01-31 | Smet Pharmaceutical Inc | ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE |
| MX2020007291A (es) * | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
-
2020
- 2020-10-14 CN CN202080072320.1A patent/CN115348972A/zh active Pending
- 2020-10-14 PE PE2022000635A patent/PE20221256A1/es unknown
- 2020-10-14 JP JP2022522653A patent/JP2022551757A/ja not_active Ceased
- 2020-10-14 US US17/769,257 patent/US20240228628A9/en not_active Abandoned
- 2020-10-14 CA CA3153801A patent/CA3153801A1/en active Pending
- 2020-10-14 BR BR112022006817A patent/BR112022006817A2/pt not_active Application Discontinuation
- 2020-10-14 WO PCT/US2020/055480 patent/WO2021076554A1/en not_active Ceased
- 2020-10-14 MX MX2022004291A patent/MX2022004291A/es unknown
- 2020-10-14 AU AU2020366000A patent/AU2020366000A1/en active Pending
- 2020-10-14 KR KR1020227016159A patent/KR20220082882A/ko not_active Ceased
- 2020-10-14 TW TW109135527A patent/TWI867066B/zh active
- 2020-10-14 AR ARP200102839A patent/AR120222A1/es unknown
- 2020-10-14 EP EP20876423.3A patent/EP4045537A4/en active Pending
-
2022
- 2022-04-12 CL CL2022000927A patent/CL2022000927A1/es unknown
- 2022-04-13 IL IL292259A patent/IL292259A/en unknown
- 2022-04-13 CO CONC2022/0004743A patent/CO2022004743A2/es unknown